ERBB2 and breast carcinoma: ,81 For anti-cancer applications, a phase I trial was held where HER2-positive breast cancer patients were administered with 131I-labeled - 4-guanidino-methyl-3-iodobenzoate (131I-GMIB)-anti-HER2-VHH1 for targeted radionuclide theragnostics.